Anorexia NervosaBIOANNANCT05885724
Novel Targetable BIOmarkers in ANorexia NervosA
An observational study of Anorexia Nervosa and Anorexia Nervosa Restricting Type, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
Trial summary
The overall aim of this present study is to evaluate Growth Differentiation Factor-15 (GDF-15) and inflammatory cytokines as a possible novel and readily treatable target for the successful therapy of Anorexia Nervosa (AN). Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Anorexia Nervosa, Anorexia Nervosa Restricting Type
- How many people
- 32 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 May 2023to 30 Apr 2025
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Patients with confirmed diagnosis of AN will be recruited via the anorexia outpatient clinic of the Endocrinology Department, University Hospital Basel, headed by Prof. Dr. Katharina Timper and via advertisement. Healthy sex- and age (+/- 3 years of age difference) control participants will be recruited at the medical and endocrinology outpatient clinic of the University Hospital of Basel and via advertisement.
Who may be able to join
- Age 18-60 years
- Written informed consent
- BMI 10-16 kg/m2
- N=8 adult male and female patients with confirmed diagnosis of anorexia nervosa restrictive type, exercising subtype will be included in this study.
- Age 18-60 years
- Written informed consent
Show all 11Show fewer
- BMI 10-16 kg/m2
- N=16 control participants, sex- and age-matched to the individual anorexia nervosa patients.
- Age 18-60 years
- Written informed consent
- BMI 19-24.9 kg/m2
Who cannot join
- Use of antibiotics within the last 31 days
- Current illicit drug abuse including daily marijuana or CBD (cannabidiol) consumption (≤ 24 g of alcohol per day allowed)
- Any kind of severe chronic disease other than AN (e.g. active cancer disease)
- Severe renal impairment (e.g. estimated glomerular filtration rate <30 ml/min/m2) if resulting from another disease than AN
- Known liver cirrhosis or other severe liver impairment if resulting from another disease than AN
- Acute upper respiratory tract infection within the last 31 days
Show all 10Show fewer
- Uncontrolled dysthyroidism
- Uncontrolled hypertension
- Current pregnancy/lactation or current treatment for in vitro fertilization
- Inability to understand the study information, to sign the consent form and to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
University Hospital Basel
Basel, 4031
Katharina Timper, Prof., +4161 328 57 42, katharina.timper@usb.ch
Valerie Mettraux, +4161 328 55 20, valerie.mettraux@usb.ch
About this study
Official title: Novel Targetable BIOmarkers in ANorexia NervosA - BIOANNA
The overall aim of this present study is to evaluate Growth Differentiation Factor-15 (GDF-15) and inflammatory cytokines as a possible novel and readily treatable target for the successful therapy of Anorexia Nervosa (AN). Therefore, GDF-15, neuronal and glial damage markers such as Neurofilament light chain (Nfl) and Glial fibrillary acidic protein (GFAP) and cytokines (such as Tumor necrosis factor alpha (TNF-α), Interleukin-6 (IL-6), and Interleukin 1β (IL-1β) levels will be assessed in the serum as well as in the cerebrospinal fluid of patients with diagnosed restrictive AN with and without exercising behavior compared to sex- and age-matched healthy controls to consolidate previous findings and to identify the main site of production of GDF-15 and cytokines in AN.
Read the detailed description
In addition, assessment of body composition via Dual Energy X-ray Absorptiometry (DEXA )scans and of energy expenditure via indirect calorimetry, respectively, will allow us to correlate GDF-15, Nfl and GFAP and cytokine levels with lean and fat mass measures as well as with energy expenditure, respectively, of AN patients and the matched controls. Overall, this will allow us to comprehensively evaluate GDF-15 and cytokines as possible novel targets for the treatment of AN and to set the basis for a follow up study using available neutralizing antibodies or inhibitors against GDF-15 and the respective cytokines for the treatment of patients with AN, respectively. This will also allow for a more tailored, individualized treatment approach of AN in the future. Our findings will hopefully challenge the viewpoint that AN is a condition which can be controlled by the individual but demonstrate that AN is a biological disease that should be treated by targeting the right biological players in addition to psychiatric treatment.
- Keywords
- exercising subtype, non-exercising subtype, Neurofilament light chain, Glial fibrillary acidic protein, Growth Differentiation Factor-15
- Medical subject headings
- Anorexia Nervosa, Charcot-Marie-Tooth disease, Type 1F
What is being measured
The primary outcome is the main question the study is designed to answer.
Growth Differentiation Factor-15 (GDF-15) (pg/ml) level in the plasma
Comparison of GDF-15 (pg/ml) level in the plasma of AN patients and normal-weight controls Blood in overnight-fasted study participants will be taken from a cubital vein and analyzed for GDF-15 (pg/ml)
Measured: one time assessment 3 weeks after screening
Growth Differentiation Factor-15 (GDF-15) (pg/ml) level in the cerebrospinal fluids
Comparison of GDF-15 level in the cerebrospinal fluids of AN patients and normal-weight controls. CSF will be analysed only from patients who undergo a liquor puncture as part of their clinical assessment and consent to having taken an extra 5ml. Cerebrospinal fluid (CSF) will then be analysed for GDF-15 (pg/ml)
Measured: one time assessment 3 weeks after screening
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jun 2023
- Study start1 May 2023
- Primary completion30 Apr 2025 (estimated)
- Study completion30 Apr 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Anorexia NervosaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 32 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Collaborators
- University of Zurich
- Responsible party
- Sponsor
- Investigators
- Katharina Timper, Prof., Principal investigator, University Hospital, Basel, Switzerland
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05885724
- Sponsor's protocol ID
- 2023-00513, kt23Timper2
- Other IDs
- 2023
- Acronym
- BIOANNA
- Status last verified
- Dec 2024
- First submitted
- 22 May 2023
- Last updated
- 12 Dec 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No